GLP-1 Medications and Fertility: What You Need to Know Before Conceiving

They're calling them "Ozempic babies" on social media — the unexpected pregnancies that seem to be happening in women taking GLP-1 medications. The phenomenon has generated enough attention to warrant a serious look at what GLP-1 medications actually do to fertility, what the risks are during pregnancy, and how to time medication use around conception.

The "Ozempic Baby" Phenomenon

The anecdotal reports are real: women who struggled with infertility for years are conceiving after starting GLP-1 medications — sometimes within months. Is this a direct fertility effect of the medication, or is something else going on?

The answer is mostly indirect — but no less real.

The Weight-Fertility Connection

Excess weight, particularly when accompanied by insulin resistance, is one of the most common causes of reduced fertility in women. The mechanisms are well-established:

Ovulatory dysfunction. Obesity and insulin resistance disrupt the hormonal cascade that triggers ovulation. Elevated insulin drives increased androgen production by the ovaries, which interferes with follicle development and ovulation. This is the core mechanism of PCOS-related infertility, but it affects anovulation more broadly.

Hormone imbalance. Adipose tissue converts androgens to estrogen (via the enzyme aromatase), creating a state of relative estrogen excess that disrupts the hypothalamic-pituitary-ovarian axis.

Endometrial receptivity. Obesity and insulin resistance may impair endometrial receptivity — the uterine lining's ability to support implantation of a fertilized egg.

When GLP-1 medications produce 15-20% weight loss, these mechanisms improve:

• Insulin resistance decreases
• Androgen levels normalize
• Ovulatory cycles resume in many anovulatory women
• Hormonal balance improves

For women with PCOS specifically, studies show that losing just 5-10% of body weight can restore spontaneous ovulation in 30-40% of anovulatory women. GLP-1-mediated weight loss typically far exceeds this threshold.

Oral Contraceptive Interaction

There's a pharmacokinetic consideration that may also contribute. GLP-1 medications slow gastric emptying, which can theoretically reduce the absorption of oral medications — including oral contraceptive pills. If oral contraceptive absorption is reduced, their effectiveness could be diminished, increasing the chance of unplanned pregnancy.

The clinical significance of this interaction is debated. The FDA labeling for semaglutide recommends monitoring for potential reduced effectiveness of oral medications, and some providers suggest using non-oral contraceptive methods (IUD, implant, patch, ring) while on GLP-1 medications to avoid any risk.

Effects on Male Fertility

The data on GLP-1 medications and male fertility is limited but mostly reassuring:

Weight loss and testosterone. Male obesity is associated with lower testosterone levels due to increased aromatization (conversion of testosterone to estrogen in fat tissue) and suppression of the hypothalamic-pituitary-gonadal axis. Weight loss through any means typically raises testosterone levels. Studies show that obese men who lose significant weight experience increases in total and free testosterone, sometimes by 20-30%.

Sperm quality. Obesity is associated with reduced sperm concentration, motility, and morphology. Weight loss generally improves these parameters, though the evidence for GLP-1-specific effects is limited.

Direct testicular effects. GLP-1 receptors are present in testicular tissue. In animal studies, GLP-1 receptor activation has shown mixed effects on testicular function. Human data is insufficient to draw firm conclusions about direct effects on spermatogenesis.

Practical guidance for men: If you're taking a GLP-1 medication and planning to conceive with your partner, there's currently no recommendation to discontinue the medication for fertility purposes. The weight loss and metabolic improvements are likely beneficial for male fertility.

The Pregnancy Safety Question

This is where caution becomes critical. GLP-1 medications are not approved for use during pregnancy and should be discontinued before conception. Here's why:

Animal Data

In animal reproductive toxicity studies, semaglutide and tirzepatide have shown adverse effects:

• Embryo-fetal death at clinically relevant or higher doses
• Structural abnormalities (birth defects) in some animal species
• Reduced fetal growth and birth weight

These findings led to the medications being classified as pregnancy Category C (animal studies show risk, no adequate human studies) or the equivalent under the newer PLLR labeling system.

Human Data

Human data on GLP-1 exposure during pregnancy is extremely limited. No controlled studies exist. Case reports and registry data are accumulating but insufficient to characterize the risk profile in humans. The absence of evidence is not evidence of absence — we simply don't know enough to declare these medications safe during pregnancy.

The Conservative Approach

Given the animal data and lack of human safety data, the standard recommendation is:

• Semaglutide: Discontinue at least 2 months before planned conception (based on the drug's elimination half-life of approximately 1 week, allowing approximately 5 half-lives for clearance)
• Tirzepatide: Discontinue at least 2 months before planned conception (similar pharmacokinetic rationale)

This 2-month washout period is not based on definitive safety data — it's a conservative approach derived from pharmacokinetics. The medication should be completely cleared from your system by 5-7 half-lives after the last dose.

Planning Pregnancy Around GLP-1 Use

For women using GLP-1 medications who plan to become pregnant, here's a practical timeline:

Phase 1: Active Treatment (3-12+ months)

• Use GLP-1 medication for weight loss and metabolic improvement
• Use reliable contraception (preferably non-oral methods)
• Address insulin resistance, optimize metabolic health
• Achieve target weight loss goals

Phase 2: Transition (2-3 months before conception attempts)

• Discontinue GLP-1 medication
• Switch to a maintenance strategy (nutrition, exercise, potentially metformin which is considered safer in early pregnancy)
• Ensure adequate folate supplementation (begin at least 1-3 months before conception)
• Address any nutritional deficiencies that may have developed during rapid weight loss
• Monitor weight — some regain is expected and should be anticipated in planning

Phase 3: Conception and Pregnancy

• GLP-1 medication should be fully cleared
• Metabolic improvements from weight loss persist even after medication discontinuation (in the short term)
• Continue healthy nutrition and activity patterns established during treatment

The PCOS-Specific Strategy

For women with PCOS-related infertility, this timeline often looks like:

1. Start GLP-1 medication to address weight and insulin resistance
2. As weight decreases and insulin sensitivity improves, monitor for return of ovulatory cycles
3. Once metabolic goals are approached, discontinue GLP-1 medication
4. Allow 2-month washout
5. Attempt conception — the improved metabolic environment may support spontaneous ovulation
6. If conception doesn't occur within 6-12 months, fertility treatment (clomiphene, letrozole, IVF) may be indicated — from a healthier metabolic starting point

Breastfeeding Considerations

GLP-1 medications are not recommended during breastfeeding. Animal studies show that semaglutide is excreted in breast milk. The effects on nursing infants are unknown. Until safety data is available, the conservative recommendation is to avoid GLP-1 medications while breastfeeding.

Unplanned Pregnancy on GLP-1 Medications

If you discover you're pregnant while taking a GLP-1 medication:

1. Stop the medication immediately. Do not take the next scheduled dose.
2. Contact your prescriber. Inform them of the pregnancy so they can advise on next steps.
3. Don't panic. The absence of extensive human data doesn't mean harm has occurred. Many women have had GLP-1 exposure in early pregnancy (before pregnancy was detected) without apparent adverse outcomes. The animal data is concerning but not directly translatable to humans at therapeutic doses.
4. Seek early prenatal care. Early ultrasound and appropriate prenatal monitoring can identify any concerns.

The Takeaway

GLP-1 medications can significantly improve fertility by addressing the metabolic dysfunction — particularly insulin resistance and obesity — that impairs reproductive function. But they should be used as a pre-conception optimization tool, not during conception or pregnancy.

At CORAL, Dr. Kim considers reproductive plans as part of the treatment discussion for all patients of reproductive age. If pregnancy is in your future, that shapes the medication strategy — what to use, how long to use it, and when to transition.

---

Planning for pregnancy and wondering how weight management fits in? A consultation can help you create a timeline that optimizes both your metabolic health and your fertility goals. [Start your evaluation at coral.clinic/start](https://coral.clinic/start).